A methods review of posttrial follow-up studies of cardiovascular prevention finds potential biases in estimating legacy effects

Zhu, Lin; Bell, Katy J.L.; Nayak, Agnish; Hayen, Andrew

doi:10.1016/j.jclinepi.2020.11.008

Cited by 2 publications

(1 citation statement)

References 20 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Reviews of the reporting and methods for post-trial legacy effects highlight that both direct effects (during the RCT timeframe) and legacy effects (during the post-trial period) contribute to the overall long-term effects of the intervention (Zhu et al 2021). All three types of effect may be of interest as the target of inference.…”

Section: Introductionmentioning

confidence: 99%

Expanded statistical analysis plan for legacy and long-term effects of aspirin in the ASPREE-XT observational follow-up study of participants in the ASPREE randomized trial

Wolfe,

Broder,

Chan

et al. 2023

Preprint

View full text Add to dashboard Cite

The ASPREE randomized controlled trial (2010-2017) of 19,114 community-dwelling older adults without cardiovascular disease and significant disability compared daily 100mg aspirin to placebo. A total of 16,317 (93%) of 17,546 surviving and non-withdrawn participants agreed to continue regular study follow-up visits in the post-trial phase, named ASPREE-XT (2017-2024). We present a statistical analysis plan to underpin three main papers to report aspirin effects through to the fourth post-trial ASPREE-XT study visit with focus areas of: (1) death, dementia, and disability, (2) CVD events and bleeding, and (3) cancer. The focus of the plan is to estimate long-term (entire timespan of RCT plus post-trial) and legacy (post-trial period only) effects of aspirin in the setting of primary prevention for older individuals. Preliminary insights to these effects are presented that are based on data that has been reported to the study's observational study monitoring board however formal data lock is not expected until October 2023.

show abstract

Section: Introductionmentioning

confidence: 99%